There is positive news for the global healthcare system, as a clinical study of 18 cancer patients has shown that it is effective in removing cancer from their bodies. According to the New York Times, Dostarlimab appears to have cured every participant who had rectal cancer in the study. Dostarlimab was used for six months, and after more than 12 months, doctors found that their cancer was gone.

They are all in a similar stage of cancer - it develops locally in the rectum, but does not spread to other organs. Dostarlimab is a drug with laboratory-made molecules that act as surrogate antibodies in the human body.

"I believe this is the first time this has happened in the history of cancer," said Dr. Luis A. Diaz Jr, the author of the paper published on Sunday in the New England Journal of Medicine, in reference to the breakthrough results. 

According to her cancer, her cancer had completely disappeared and was not very detectable on physical examination; endoscopy; positron emission tomography of PET scan or MRI scan.

The researchers, published in the New England Journal of Medicine on Sunday, wrote: "At the time of this report, no patients had been treated with hemoradiotherapy or surgery, and no progression or recurrence had been reported during follow-up."

Meanwhile, Memorial Sloan Kettering Cancer Center and co-author of the article, oncologist Dr. Andrea Cercek, described a moment when patients knew they did not have cancer. "There were a lot of happy tears," he told the New York Times.

The final result of this trial has shocked experts around the globe and they have pointed out that complete remission in every single patient is “unheard-of". Although the trial size was small, Dostarlimab can be a potential cure for one of the deadliest common cancers.